385 related articles for article (PubMed ID: 10333912)
1. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H
Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912
[TBL] [Abstract][Full Text] [Related]
2. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide versus glyburide: a one-year comparison trial.
Marbury T; Huang WC; Strange P; Lebovitz H
Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.
Soegondo S; Subekti I; Luthariana L
Acta Med Indones; 2004; 36(3):142-7. PubMed ID: 15557683
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Wang W; Bu R; Su Q; Liu J; Ning G
Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
8. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Wolffenbuttel BH; Landgraf R
Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
[TBL] [Abstract][Full Text] [Related]
9. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide in combination therapy with metformin in Type 2 diabetes.
Moses R
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S136-9. PubMed ID: 10522839
[TBL] [Abstract][Full Text] [Related]
11. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.
Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
Diabetes Care; 2002 Oct; 25(10):1685-90. PubMed ID: 12351462
[TBL] [Abstract][Full Text] [Related]
16. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
[TBL] [Abstract][Full Text] [Related]
17. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
[TBL] [Abstract][Full Text] [Related]
18. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets.
Moses RG
Clin Ther; 2008 Mar; 30(3):552-4. PubMed ID: 18405794
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
20. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
